Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0852W HIGH $9.08
Volume
486.07 K
Value Traded
885.33 K
Short % Float
9.53%
-16.36%Week
+0.9%1 Month
-12.28%3 Month
-30.77%6 Month
-99.75%5 Year
-99.75%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
179.28 M
EPS (TTM)
-1.23
P/E Ratio
-
Ent. Value
142.04 M
Total Shares
79.68 M
Float Shares
71.12 M
Insiders
10.75%
Institutions
28.11%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CNTN Catalyst Timeline
Dated clinical, regulatory and corporate events for Canton Strategic Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Canton Strategic Holdings, Inc.
29Total events
0Upcoming
7Tier-1 (high impact)
2023 to 2026Coverage
Event history 27
●Quarterly UpdateCorporate
Corporate rebrand to Canton Strategic Holdings, Inc. and NASDAQ ticker change to CNTN
▼Equity OfferingCorporate
Pricing of $1.74 million registered direct public offering of common stock and warrants
◆First Patient DosedTH104Trial
Expects to complete Phase 2 trial in chronic pruritis over approximately 12 months after aligning with FDA on trial design
chronic pruritis in PBCsource ↗
◆Topline ReadoutTH104Clinical Data
Topline data from Phase 2 trial in chronic pruritis expected approximately 12 months after FDA alignment
chronic pruritis in PBCsource ↗
▲Partnership / LicenseINT-023Corporate
Tharimmune acquires global license from Intract Pharma for oral infliximab formulation
autoimmune diseasessource ↗
▼Reverse Stock SplitCorporate
1-for-15 reverse stock split effective after market close on May 24, 2024
◆Topline ReadoutTH104Clinical Data
Topline data expected for Phase 1 PK bridging study in US
chronic pruritis in primary biliary cholangitissource ↗
◆Trial InitiationTH104Trial
Phase 2a trial to be launched next year in chronic pruritis in PBC
chronic pruritis in primary biliary cholangitissource ↗
◆Trial CompletionTH104Trial
Completion of Phase 1 pharmacokinetic trial by year-end 2023
pruritis in primary biliary cholangitissource ↗
▲Topline ReadoutTH104Clinical Data
Positive Phase 1 data for TH104 in chronic pruritis in PBC
chronic pruritis in primary biliary cholangitissource ↗
▲Partnership / LicenseAV104Corporate
Exclusive global licensing agreement for AV104 (to be renamed TH104) with Avior Bio
chronic pruritissource ↗
◆AcquisitionTH104Corporate
Acquisition of TH104 expected to close in Q4 2023
pruritis in primary biliary cholangitissource ↗
◆Trial InitiationTH104Trial
Launch of Phase 1 pharmacokinetic trial in Q4 2023
pruritis in primary biliary cholangitissource ↗
●Quarterly UpdateCorporate
Corporate name change to Tharimmune, Inc. effective September 25, 2023
▼Equity OfferingCorporate
Hillstream BioPharma announces proposed public offering of common stock and/or pre-funded warrants
●IND SubmissionHSB-1216IND
Hillstream anticipates submitting IND for HSB-1216 in second half of 2023
drug resistant cancerssource ↗
▲Trial InitiationHSB-1216Trial
Hillstream plans to initiate clinical study with HSB-1216 in second half of 2023
drug resistant cancerssource ↗
Past FDA Catalysts and PDUFA Decisions
How CNTN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Canton Strategic Holdings, Inc. is not a drug developer. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CNTN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TH104 | chronic pruritus in primary biliary cholangitis (PBC) | Phase 1 | 2023-11-27 | Cmax: higher than the tablet product; AUC0: higher than the tablet product; safety: no deaths, other serious adverse events, or other significant adverse events reportedRead More | Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC) Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic pRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Stetz Gary S.Director | Sell | -12,500 134,175 held | $3.47 | 05/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CNTN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CNTN for Q2 2026. | ||||
CNTN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CNTN ranks across every disease it competes in
Competitive Position is a premium feature
See how CNTN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCNTN News
CNTNCanton Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational Results
Canton Strategic Holdings, Inc. reported its first operating revenue in Q2 2026, driven by its Super Validator and locking-as-a-service operations. The company generated approximately $1.3 million from its LaaS offering and $191,226 from validation services. Despite these achievements, it reported a net loss of $19.25 million, highlighting ongoing challenges in profitability.
Read more →CNTNThree New Directors Elected to the Board of Canton Strategic Holdings, Inc.
Canton Strategic Holdings, Inc. has elected three new directors to its Board, effective July 13, 2026. Sean Galvin, Pamela L. Carter, and Rishi Nangalia bring significant expertise in financial markets, governance, and technology. Their appointments are expected to enhance the company's strategic direction as it advances its Canton Network strategy.
Read more →CNTNCanton Strategic Holdings, Inc. Announces Sale of Gravitas Life Sciences, LLC
Canton Strategic Holdings, Inc. has announced the sale of its biotech arm, Gravitas Life Sciences, to Gravitas Collective Corp. This transaction, which closed on July 17, 2026, was unanimously approved by the Board of Directors. The sale allows the company to concentrate on its Canton Network strategy aimed at digitizing traditional financial markets.
Read more →CNTNCanton Strategic Holdings, Inc. Delivers Second Quarter Canton Network Ecosystem Update
Canton Strategic Holdings, Inc. has released its second quarter ecosystem report, highlighting governance milestones and increased institutional adoption on the Canton Network. The company will host a webinar on July 22, 2026, to discuss the report's findings and the network's evolution. Notably, the report mentions a successful pilot of US Treasury tokenization.
Read more →CNTNCanton Strategic Holdings, Inc. Announces Launch of Locking Service to Support Network Infrastructure Providers
Canton Strategic Holdings, Inc. has announced the launch of a new locking service aimed at supporting network infrastructure providers within the Canton Network. This service, which follows the approval of two Canton Improvement Proposals, is designed to enhance liquidity and optimize capital efficiency for Super Validators and app builders. The initiative reflects a commitment to a robust tokenomics policy that aligns incentives for network participants.
Read more →CNTN▼ -5.4%on this news· ran to -25% by day 3shared move
Canton Strategic Holdings, Inc. Expected to Be Included in Russell 3000® and Russell 2000®
Canton Strategic Holdings, Inc. (NASDAQ: CNTN) is set to join the Russell 3000® and Russell 2000® indices after the semi-annual reconstitution on June 26, 2026. This inclusion highlights the company's unique position in leveraging Canton Coin to digitize financial markets. CEO Mark Wendland emphasized the significance of this recognition for broader investor engagement.
Read more →CNTNCanton Strategic Holdings, Inc. Announces Authorization of Share Repurchase Program
Canton Strategic Holdings, Inc. has announced a $50 million share repurchase program, reflecting confidence in its platform's strength and long-term value for shareholders. The program allows the company to repurchase shares based on market conditions, share price, and other factors. This initiative is aligned with Canton Strategic's mission to enhance the institutional adoption of the Canton Network and its related technologies.
Read more →CNTN▲ +7.3%on this news
Canton Strategic Holdings Reports First Quarter 2026 Financial and Operational Results
Canton Strategic Holdings, Inc. reported its Q1 2026 financial results, highlighting operational advancements and a strengthened capital position. The company secured approval to operate as a Super Validator and launched commercial token locking solutions. Despite a net loss of $47.3 million, the company aims to drive revenue through its digital asset strategy and partnerships in the Canton Network.
Read more →CNTNCanton Strategic Holdings, Inc. Presents Quarterly Canton Network Ecosystem Update
Canton Strategic Holdings, Inc. has released its quarterly ecosystem update for Q1 2026, highlighting key adoption milestones and transaction growth within the Canton Network. The report will be followed by a live webinar on April 22, 2026, where company leadership will discuss insights and tokenomics. This marks the company's commitment to advancing blockchain adoption in financial markets.
Read more →CNTN▲ +6.2%on this news
Canton Strategic Holdings Reports Full Year 2025 Financial and Operational Results First Annual Report Since Establishing Canton Network Digital Asset Strategy Highlights Accelerating Network Momentum and Strengthened Ca
Canton Strategic Holdings, Inc. reported its financial and operational results for the year ending December 31, 2025, marking the first annual report since establishing its digital asset strategy. The company highlighted a significant partnership with institutions and substantial holdings in Canton Coin, valued at over $501 million. However, it also faced challenges, including a net loss of $35.9 million and increased operating expenses amid the strategy's transition. Looking forward, the firm aims to enhance its capital base and implement disciplined expense management to bolster its growth in the evolving blockchain landscape.
Read more →CNTN▼ -10.1%on this news
Canton Strategic Holdings, Inc. Chairman and CEO Mark Wendland Elected to Canton Foundation Board Appointment Underscores Canton Strategic Holdings' Leadership Role in Accelerating Institutional Adoption of the Canton Ne
Canton Strategic Holdings, Inc. announced the election of Chairman and CEO Mark Wendland to the Canton Foundation Board. This appointment signifies the company's leadership role in facilitating institutional adoption of the Canton Network, especially in the digitization of financial markets. The Canton Foundation oversees governance and operational standards within the network, making Wendland's membership pivotal for strengthening the network's credibility in the financial ecosystem.
Read more →CNTNCONFIDENTIAL DRAFT Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy New NASDAQ Ticker Symbol "CNTN" to Begin Trading
Tharimmune, Inc. has announced a corporate rebrand to Canton Strategic Holdings, Inc., effective February 18, 2026. This rebranding is part of their strategy to support institutional adoption of the Canton Network, which focuses on digital asset treasury initiatives. With this change, their stock will begin trading under the new ticker symbol 'CNTN'. Highlights of this announcement include securing Super Validator status and enhancing institutional expertise on their Board of Directors.
Read more →CNTNTharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Le
Tharimmune, Inc. has appointed Mark Wendland as Chairman of the Board and Angela Radkowski as Chief Operating Officer, effective February 5, 2026. This leadership expansion aims to support the execution of the company's Canton Network strategy, which seeks to modernize financial market infrastructure using Canton Coin. Wendland and Radkowski bring significant industry experience and are expected to drive institutional adoption of the Canton Network, thereby enhancing shareholder value. The company focuses on bridging traditional financial markets with digital asset capabilities.
Read more →CNTNTharimmune Elects Jill Sommers and William Wiley to Board of Directors New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulat
Tharimmune, Inc. has elected Jill Sommers and William Wiley to its Board of Directors, effective February 1, 2026. Sommers, a former CFTC Commissioner, and Wiley, a seasoned capital markets expert, are expected to enhance the company's governance as it pursues its Canton Network strategy. Tharimmune aims to digitize traditional financial markets using Canton Coin and improve the financial infrastructure with their expertise. The additions reflect the company's commitment to compliance and modernization in the blockchain space.
Read more →CNTNTharimmune Announces Expanded Role as Super Validator on Canton Network Advances Digital Asset Treasury Strategy Through Contributions to Canton Network
Tharimmune, Inc. has announced its approval to function as a Super Validator on the Canton Network, enhancing its efforts in digitizing traditional financial markets. The role aims to secure transactions and generate rewards in Canton Coin, bolstering the company's digital asset treasury. CEO Mark Wendland highlighted the impact of the Canton Network on global financial infrastructure, while Tharimmune plans to support the adoption of institutional applications utilizing this technology. This collaboration positions Tharimmune as a key player in transforming financial markets through blockchain innovation.
Read more →CNTNTharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering
Tharimmune, Inc. has successfully closed a $55 million underwritten registered direct offering, issuing 1,800,000 shares at $2.92 each. The funds raised will be used to support the company's Canton-centric digital asset treasury strategy and provide working capital for corporate needs. This offering signifies Tharimmune's commitment to enhancing its growth potential in the blockchain and financial markets.
Read more →CNTNTharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering
Tharimmune, Inc. has announced the pricing of an underwritten registered offering, raising $55 million through the issuance of 1,800,000 shares at $2.92 each. The capital is intended for the expansion of its digital asset treasury strategy leveraging the Canton Network and for general corporate purposes. The offering, which includes pre-funded warrants for additional shares, is expected to close on January 21, 2026, subject to customary conditions. This initiative marks a strategic step in advancing the company's blockchain-related financial operations.
Read more →CNTNTharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy Former Clear Street Group CFO Strengthens Leadership Team Alongside Industry Veterans Mark Wendland and Mark Toom
Tharimmune, Inc. has appointed Jacob Asbury as its Chief Financial Officer, effective immediately. Asbury, who brings nearly two decades of financial leadership experience, will oversee financial strategy and operations to enhance the company's Canton Coin treasury strategy. His appointment reflects Tharimmune's commitment to innovating financial markets through the Canton Network. Asbury aims to create long-term value for shareholders and enhance the adoption of digital assets in institutional markets.
Read more →CNTNTharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy Led by DRW and Liberty City Ventures, Transaction Cements Tharimmune as First Public Company to Deliver Canton-Aligned DAT
Tharimmune, Inc. has successfully closed a $545 million private placement aimed at establishing a Canton Coin treasury strategy, becoming the first public company to engage with the Canton Network. The raised funds will be utilized to acquire the Canton Coin utility token and support the company's role as a Super Validator in the network. With leadership changes including a new CEO and President, Tharimmune aims to execute a differentiated digital asset strategy that promotes institutional adoption of blockchain technology. The private placement was backed by notable investors, highlighting confidence in Tharimmune's future.
Read more →About Canton Strategic Holdings, Inc.
Headquarters1460 BROADWAY, NEW YORK, NY, 10036
BIOPHARMAWATCH ELITE PLUS
Trade the next CNTN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime